A phase I safety and tolerability study of vorinostat (V) in combination with sorafenib (S) in patients with advanced solid tumors, with exploration of two tumor-type specific expanded cohorts at the recommended phase II dose (renal and non-small cell lung carcinoma).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 2562-2562 ◽  
Author(s):  
A. Dasari ◽  
L. Gore ◽  
W. A. Messersmith ◽  
S. Diab ◽  
A. Jimeno ◽  
...  
Lung Cancer ◽  
2001 ◽  
Vol 32 (2) ◽  
pp. 189-196 ◽  
Author(s):  
Ajeet Gajra ◽  
Syed A. Mehdi ◽  
Jeffery Kirshner ◽  
Nancy Newman ◽  
Stephen L. Graziano

2011 ◽  
Vol 6 (1) ◽  
pp. 17 ◽  
Author(s):  
Xinglei Shen ◽  
Albert DeNittis ◽  
Maria Werner-Wasik ◽  
Rita Axelrod ◽  
Paul Gilman ◽  
...  

2019 ◽  
Vol 113 ◽  
pp. 87-95 ◽  
Author(s):  
Daniel R. McGowan ◽  
Michael Skwarski ◽  
Kevin M. Bradley ◽  
Leticia Campo ◽  
John D. Fenwick ◽  
...  

1984 ◽  
Vol 70 (5) ◽  
pp. 433-437 ◽  
Author(s):  
Maria Teresa Nobile ◽  
Riccardo Rosso ◽  
Fulvio Brema ◽  
Angela Cinquegrana ◽  
Leonardo Santi

Sign in / Sign up

Export Citation Format

Share Document